Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-4.21% $2.73
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 31.21 mill |
EPS: | -3.57 |
P/E: | -0.760 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 11.43 mill |
Avg Daily Volume: | 0.231 mill |
RATING 2024-04-17 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.760 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.13x |
Company: PE -0.760 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.01 (10.29%) $0.281 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 2.39 - 3.07 ( +/- 12.45%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-19 | Shefferman Jesse | Buy | 59 000 | Common Stock |
2024-01-19 | Shefferman Jesse | Sell | 7 803 | Common Stock |
2024-01-19 | Shefferman Jesse | Buy | 357 000 | Stock Option (Right to Buy) |
2024-01-19 | Bandari Jathin | Buy | 137 000 | Stock Option (Right to Buy) |
2024-01-19 | Bandari Jathin | Buy | 23 000 | Common Stock |
INSIDER POWER |
---|
91.92 |
Last 95 transactions |
Buy: 2 372 974 | Sell: 114 915 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.73 (-4.21% ) |
Volume | 0.174 mill |
Avg. Vol. | 0.231 mill |
% of Avg. Vol | 75.36 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.